|
1) Sandborn WJ, Colombel JF, et al. A placebo-controlled trial of visilizumab in patients with intravenous (iv) steroid refractory ulcerative colitis (UC). Gastroenterology. 2009; 136 Suppl 1: A-64
|
|
|
|
|
2) Sands BE, Sandborn WJ, et al. A randomized, double-blind, placebo-controlled trial of basiliximab with concomitant corticosteroids in steroid-refractory ulcerative colitis. Gastroenterology. 2009; 136(Suppl 1): A-65
|
|
|
|
|
|
3) Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006; 2: 619-26
|
|
|
|
|
4) Mitsuyama K, Toyonaga A, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut. 1995; 36: 45-9
|
|
|
|
|
|
5) Genovese MC, Becker JC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005; 353: 1114-23
|
|
|
|
|
|
6) Hommes DW, Mikhajlova TL, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006; 55: 1131-7
|
|
|
|
|
|
7) Sandborn WJ, Feagan BG, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008; 135: 1130-41
|
|
|
|
|
|
8) Sandborn WJ, Colombel JF, et al. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353: 1912-25
|
|
|
|
|
|
9) Van Assche G, Van Ranst M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005; 353: 362-8
|
|
|
|
|
|
10) Targan SR, Feagan BG, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007; 132: 1672-83
|
|
|
|
|
|
11) Feagan BG, Greenberg GR, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005; 352: 2499-507
|
|
|
|
|
|
12) Keshav S, Johnson D, et al. PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate to severe Crohn's disease. Gastroenterology. 2009; 136 Suppl 1: A-65
|
|
|
|
|
|
13) Feagan BG, Anderson F, et al. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of n. o. v. e. l. 4, a Phase III multicenter study. Gastroenterology. 2007; 132(Suppl 2): A-103
|
|
|
|
|
|
14) Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther. 2005; 21: 391-400
|
|
|
|
|
|
15) Silverman J, Liu Q, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol. 2005; 23: 1556-61
|
|
|
|
|
|
16) Peyrin-Biroulet L, Desreumaux P, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008; 372: 67-81
|
|
|
|
|